期刊文献+

两例Ph染色体阳性慢性粒细胞白血病患者具有少见型bcr/abl融合基因 被引量:6

Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene
原文传递
导出
摘要 目的 研究 2例Ph染色体阳性慢性粒细胞白血病慢性期 (CML CP)患者异常的bcr/abl融合基因结构。方法 分别采用常规的M 及 μ 型bcr/abl融合转录子特异性引物进行逆转录 聚合酶链反应 (RT PCR) ,对RT PCR扩增产物测序进行序列同源性分析 ,以确定扩增产物的成分及bcr/abl融合转录子类型 ,其中 1例根据测序结果设计引物并通过PCR研究其DNA水平bcr与abl基因融合方式。结果  2例患者临床表现均符合典型CML CP特征 ,RT PCR扩增后均未见典型的M 及 μ 型扩增带 ,而分别出现一条异常的条带 ,产物大小分别介于M 及 μ bcr/abl之间及小于M bcr/abl。经序列分析证明RT PCR产物均含有bcr及abl基因序列 ,例 1的bcr基因断裂发生在第 18外显子 (e18)内部 ,abl基因融合位点为常见的外显子 2 (a2 )处 ,它们之间插入了 4 0bp的部分abl基因内含子 1b序列 ,为一种新型的符合阅读框架结构的bcr/abl融合转录子e18 int a2。经PCR证明该融合发生在DNA水平。例 2的融合转录子中缺失典型M bcr/abl(b2a2 )融合基因中abl基因外显子 2 (a2 ) ,为e13a3(b2a3)型。结论 少见型bcr/abl融合基因可见于典型Ph染色体阳性CML患者并产生异常的RT PCR扩增带。 Objective To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia(CML) patients in chronic phase(CP). Methods By using general M and μ bcr/abl specific primers respectively,bcr/abl fusion transcripts were detected by reverse transcription polymerase chain reaction (RT PCR). The RT PCR products sequencing was performed, the DNA sequences were analyzed in Genebank and the bcr and abl sequences at the fusion site were identified. DNA was amplified by PCR using a set of primers designed according to the sequencing result of RT PCR products. Results Two patients showed typical manifestations of CML CP. Their RT PCR products were different from usual M or μ type; one was longer than M bcr/abl but shorter than μ bcr/abl ,the other one was shorter than M bcr/abl. The RT PCR products sequencing showed that both products contained bcr and abl gene sequences. The first patient’s bcr gene was broken within exon 18, and fused to abl gene exon 2(a2), and a 40 bp of partial abl intron 1b fragment was inserted between them,resulting in a novel in frame bcr/abl fusion transcript——e18 int a2 which has not been reported in the literature so far. In the second patient, deletion of abl exon2(a2) led to exon 13(b2) of bcr gene fusing with abl exon 3(a3). Conclusion Uncommon bcr/abl fusion gene may occur in typical Ph(+) CML patient.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2004年第7期409-412,共4页 Chinese Journal of Hematology
关键词 PH染色体 阳性 慢性粒细胞白血病 BCR/ABL融合基因 CML-CP 逆转录聚合酶链反应 Leukemia,myeloid,chronic Fusion proteins, bcr/abl In-frame Reverse transcription polymerase chain reaction Sequence analysis
  • 相关文献

参考文献7

  • 1Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood,1996,88: 2375-2384.
  • 2Pane F,Intrieri M,Quintarelli C,et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene,2002,21:8652-8667.
  • 3Roman J,Parziale A,Gottardi E,et al. Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplant. Br J Haematol, 2000, 111:644-646.
  • 4Iwata S, Mizutani S, Nakazawa S, et al. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia, 1994,8:1696-1702.
  • 5Otazu IB, Belen Rivero M, Olicio R,et al. A rare, in-frame BCRABL fusion (e13a3) in a patient with aggressive chronic myeloid leukaemia. Acta Haematol, 2002,108:150-153.
  • 6刘艳荣,于弘,常艳,陈珊珊.四色荧光标记抗体在白血病免疫分型中的应用及意义[J].中国实验血液学杂志,2002,10(5):423-427. 被引量:43
  • 7秦亚溱,刘艳荣,李金兰,王卉,常艳,付家瑜,阮国瑞,丘镜滢,陆道培,陈珊珊.慢性髓系白血病不同bcrabl融合基因转录子与临床关系的研究[J].中华血液学杂志,2003,24(7):347-350. 被引量:20

二级参考文献18

  • 1陈珊珊,薛文韬,张海帆,付家瑜,李鲲,常艳,付剑峰,吴萍娜.成人急性白血病免疫表型的特点[J].中华血液学杂志,1995,16(1):17-19. 被引量:20
  • 2Melo JV. The diversity of bcr-abl fusion proteins and their relationship to leukemia phenotype. Blood, 1996,88: 2375-2384.
  • 3Kwok S, Higuchi R . Avoiding false positives with PCR. Nature, 1989,339 : 237-238.
  • 4Pane F, lntrieri M, Quintarelli C, et al. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene, 2002,21:8652-8667.
  • 5Perego RA, Costantini M, Comacchini G, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer, 2000,36 : 1395-1401.
  • 6Inokuchi K, Inoue T, Tojo A, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphiapositive chronic myelogenous leukemia Blood, 1991 , 78 : 3125-3127.
  • 7Saglio G, Pane F, Gottardi E, et al. Consistent amounts of acute leukemiaassociated P190^BCH/ABI transcripts are expressed by CML patients at diagnosis. Blood, 1996, 87:1075-1080.
  • 8van Rhee F, Hochhaus A, Lin F, et al. P190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood, 1996, 87:5213-5217.
  • 9Hur M,Song EY, Kang SH, et al. Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia. Arm Hematol , 2002,81 : 219-223.
  • 10Yamaguchi H, lnokuchi K, Yokomizo E, et al. Philadelphia chromosomepositive acute myeloid leukemia with tetraploidy. In J Haematol, 2002,75 : 63-67.

共引文献61

同被引文献38

  • 1邓明凤,王昌富,张万胜,李琳芸,彭长华,陈永玲.慢性髓细胞白血病患者染色体分析及bcr/abl融合基因转录本定量的临床意义[J].临床检验杂志,2006,24(3):179-181. 被引量:5
  • 2Melo JV. The diversity of BCR/ABL fusion proteins and their relationship to leukemia phenotype. Blood ,1996,88:2375-2384.
  • 3Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol, 1997, 10:203-222.
  • 4Snyder DS, MeMahon R, Cohen SR, eL al. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory. Am J Hematol, 2004,75: 92- 95.
  • 5Liu LG, Tanaka H, Ito K,et al. Chronic: myelogenous leukemia with e13a3 ( b2a3 ) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3. Am J Hematol, 2003, 74 : 268-272.
  • 6Pienkowska-Grela B, Woroniecka R, Solarska I,et al. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with a typical karyotype and BCR-ABL b2a3 transcript. Cancer Genet Cytogenet, 2007, 174: 111-115.
  • 7Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist, 2003,8:531 - 538.
  • 8Cardama AQ, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.Blood, 2005,105:2281 - 2286.
  • 9Hawkins LM, Jayanthan AA, Narendran A, et al. Effects of 17-Al-lylamino-17-Demethoxygeldanamycin (17-AAG) on Pediatric Acute Lymphoblastic Leukemia (ALL) with Respect to Ber-Abl Status and Imatinib Mesylate Sensitivity. Pediatr Res, 2005,57:430-437.
  • 10Storlazzi CT, Anelli L, Surace C, et al. Molecular cytogenetic characterization of a complex rearrengement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia. Cancer Genet Cytogenet, 2002,136 : 141 - 145.

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部